Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens

Journal of Pharmacology and Experimental Therapeutics

Volumn 278, Issue 2, 1996, Pages 547-554

  Wagstaff, John D ^b   Gibb, James W ^a   Hanson, Glen R ^a  

^a UNIVERSITY OF UTAH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; ETICLOPRIDE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID; NEUROTENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ABUSE; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

ANIMALS; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; MICRODIALYSIS; NEUROTENSIN; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030440895     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. AZZI, M., NICOT, A., GULLY, D., KITABGI, P., BÉROD, A. AND RESTÉNE, W.: Increase in neurotensin receptor expression in rat brain induced by chronic treatment with the nonpeptide neurotensin antagonist SR 48692, Neurosci. Lett. 172: 97-100, 1994.
2. BEAN, A. J., DURING, M. J., DEUTCH, A. Y. AND ROTH, R. H.: Effects of dopamine depletion on striatal neurotensin: Biochemical and immunohistochemical studies. Neuroscience 9: 4430-4438, 1989.
3. BRESLIN, N. A., SUDDATH, R. L., BISSETTE, G., NEMEROFF, C. B., LOWRIMORE, P. AND WEINBERGER, D. R.: CSF concentrations of neurotensin in schizophrenia: An investigation of clinical and biochemical correlates. Schizophr. Res. 12: 35-41, 1994.
4. 3H]neurotensin binding by unilateral intrastriatal 6-hydroxydopamine injections: Evidence from a receptor autoradiographic study. Br. Res. 564: 37-44, 1991.
5. CASTEL, M.-N., MORINO, P. AND HÖKFELT, T.: Modulation of the neurotensin striato-nigral pathway by D1 receptors. Neuroreport 5: 281-284, 1993a.
6. CASTEL, M.-N., MORINO, P., DAGERLIND, A. AND HÖKFELT, T.: Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment. Eur. J. Neurosci. 6: 646-656, 1993b.
7. CASTEL, M.-N., MORINO, P., NYLANDER, I., TERENIUS, L. AND HOKFELT, T.: Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat. Eur. J. Pharmacol. 262: 1-10, 1994.
8. CHAPMAN, M. A., SEE, R. E. AND BISSETTE, G.: Neurotensin increases extracellular striatal dopamine levels in vivo. Neuropeptides 3: 175-183, 1992.
9. ELDE, R., SCHALLING, M., CECCATELLI, S., NAKANISHI, S. AND HÖKFELT, T.: Localization of neuropeptide receptor mRNA in rat brain: initial observations using probes for neurotensin and substance P receptors. Neurosci. Lett. 120: 134-138, 1990.
10. ERVIN, G. N., BIRKEMO, L. S., NEMEROFF, C. B. AND PRANGE, A. J.: Neurotensin blocks certain amphetamine-induced behaviors. Nature 291: 73-76, 1981.
11. GULLY, D., CANTON, M., BOIGEGRAIN, R., JEANJEAN, F., MOLIMARD, J., PONCELET, M., GUEUDET, C., HEAULME, M., LEYRIS, R., BROUARD, A., PELAPRAT, D., LABBE-JULLIE, C., MAZELLA, J., SOUBRIE, P., MAFFRAND, J., ROSTENE, W., KITABGI, P. AND LE FUR, G.: Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U.S.A. 90: 65-69, 1993.
12. GYGI, S. P., GIBB, J. W. AND HANSON, G. R.: Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. J. Pharmacol. Exp. Ther. 270: 192-197, 1994.
13. HANSON, G. R., SINGH, N., MERCHANT, K., JOHNSON, M., BUSH, L. AND GIBB, J. W.: Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse: involvement of dopaminergic mechanisms. In The Neurobiology of Neurotensin, ed. by P. Kitabgi and C. B. Nemeroff, vol. 668, pp. 165-172, New York Academy of Science, New York, 1992.
14. HÖKFELT, T., CASTEL, M., MORINO, P., ZHANG, K. AND DAGERLIND, A.: General overview of neuropeptides. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. Bloom and D. Kupfer, pp. 483-492, Raven Press, New York, 1995.
15. HÖKFELT, T., EVERITT, B. J., THEODORSSON-NORHEIM, E. AND GOLDSTEIN, M.: Occurrence of neurotensin like immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J. Comp. Neurol. 222: 543-559, 1984.
16. HORGER, B. A., TAYLOR, J. R., ELSWORTH, J. D. AND ROTH, R. H.: Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacol. 11: 215-222, 1994.
17. JENNES, L., STUMPF, W. E. AND KALIVAS, P. W.: Neurotensin topographical distribution in rat brain by immunohistochemistry. J. Comp. Neurol. 210: 211-224, 1982.
18. KITABGI, P., CARRAWAY, R., VAN RIETCHOTEN, J., GRANIER, C., MORGAT, J. L., MENDEZ, A., LEEMAN, S. AND FREYCHET, P.: Neurotensin: Specific binding to synaptic membranes from rat brains. Proc. Natl. Acad. Sci. U.S.A. 74: 1846-1850, 1977.
19. KITABGI, P.: Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochem. Int. 14: 111-119, 1989.
20. KITABGI, P., DE NADAI, F., ROVÉRE, C. AND BIDARD, J.-N.: Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. In The Neurobiology of Neurotensin, vol. 668, ed. by P. Kitabgi P. and C. B. Nemeroff, pp. 30-42, New York Academy of Sciences, New York, 1992.
21. KOBAYASHI, R. M., BROWN, M. AND VALE, W.: Regional distribution of neurotensin and somatostatin in rat brain. Br. Res. 126: 584-588, 1977.
22. LAPPALAINEN, J., KIETALA, J., KOULU, M., SJOHLM, B. AND SYVALAHTI, E.: Effects of acute administration of SCH 23390 on dopamine and serotonin turnover in major dopaminergic areas and mesencephalic raphe nuclei-comparison with ritanserin. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 15: 861-872, 1991.
23. LEAKE, A. AND FERRIER, I.: Alterations in neuropeptides in aging and disease, pathophysiology and potential for clinical intervention. Drugs Aging 3: 408-427, 1993.
24. LETTER, A. A., MATSUDA, L. A., MERCHANT, K. M., GIBB, J. W. AND HANSON, G. R.: Characterization of dopaminergic influence on striatal-nigral neurotensin systems. Br. Res. 422: 200-203, 1987a.
25. LETTER, A. A., MERCHANT, K. M., GIBB, J. W. AND HANSON, G. R.: Effect of methamphetamine on neurotensin concentrations in rat brain regions. J. Pharmacol. Exp. Ther. 241: 443-447, 1987b.
26. LINDSTROM, L. H., WIDERLOV, E., BISSETTE, G. AND NEMEROFF, C. B.: Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophr. Res. 1: 55-59, 1988.
27. MAIDMENT, N. T., SIDDALL, B. J., RUDOLPH, V. R., ERDELYI, E. AND EVANS, C. J.: Dual determination of extracellular cholecystokinin and neurotensin fragments in rat forebrain: Microdialysis combined with a sequential multiple antigen radioimmunoassay. Neuroscience 45: 81-93, 1991.
28. MERCHANT, K. M., LETTER, A. A., JOHNSON, M., STONE, D. M., GIBB, J. W. AND HANSON, G. R.: Effects of amphetamine analogs on neurotensin concentrations in the rat brain. Eur. J. Pharmacol. 138: 151-154, 1987.
29. MERCHANT, K. M., LETTER, A. A., GIBB, J. W. AND HANSON, G. R.: Changes in limbic neurotensin systems induced by dopaminergic drugs. Eur. J. Pharmacol. 153: 1-9, 1988.
30. MERCHANT, K. M., GIBB, J. W. AND HANSON, G. R.: Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and nucleus accumbens. Eur. J. Pharmacol. 160: 409-412, 1989.
31. MERCHANT, K. M., HANSON, G. R. AND DORSA, D. M.: Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: Comparison with acute haloperidol effects. J. Pharmacol. Exp. Ther. 269: 806-812, 1994.
32. MIDGLEY, L. P., WAGSTAFF, J. D., SINGH, N. A., BUSH, L. G., GIBB, J. W. AND HANSON, G. R.: Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. Eur. J. Pharmacol. 251: 191-199, 1994.
33. NEMEROFF, C. B., LUTTINGER, D., HERNANDEZ, D. E., MAILMAN, R. B., MASON, G. A., DAVIS, S. D., WIDERLOV, E., FRYE, F. G. D., KILTS, C. D., BEAUMONT, K., BREESE, G. R. AND PRANGE, A. J., JR.: Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 226: 337-345, 1983.
34. NEMEROFF, C. B.: The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 11: 15-37, 1986.
35. NEMEROFF, C. B., BISSETTE, G., WIDERLOV, E., BECKMANN, H., GERNER, R., MANBERG, P. J., LINDSTROM, L. H., PRANGE, A. J. AND GATTAZ, W. F.: Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome. J. Neuropsychiatry 1: 16-20, 1989.
36. PAXINOS, P. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates. Academic Press, New York, 1982.
37. QUIRION, R., CHIUEH, C. C., EVERIST, H. E. AND PERT, A.: Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. Br. Res. 327: 385-389, 1985.
38. SCHMIDT, C. J., RITTER, J. K., SONSALLA, P. K., HANSON, G. R. AND GIBB, J. W.: Role of dopamine in the neurotoxic effects of methamphetamine. J. Pharmacol. Exp. Ther. 233: 539-544, 1985.
39. SCHOTTE, A. AND LEYSON, J. E.: Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain. J. Chem. Neuroanat. 2: 253-527, 1989.
40. SINGH, N. A., BUSH, L. G., GIBB, J. W. AND HANSON, G. R.: Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors. Eur. J. Pharmacol. 187: 337-344, 1990.
41. SINGH, N. A., BUSH, L. G., GIBB, J. W. AND HANSON, G. R.: Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems. Br. Res. 571: 260-264, 1992.
42. SKOOG, K. M., CAIN, S. T. AND NEMEROFF, C. B.: Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine. Neuropharmacology 25: 777-782, 1986.
43. SNYDER, S. H., BANERJEE, S. P., YAMAMURA, H. I. AND GREENBURG, D.: Drugs, neurotransmitters and schizophrenia. Science 184: 1243, 1974.
44. STEINBERG, R., BRUN, P., FOURNIER, M., SOUILHAC, J., RODIER, D., MONS, G., TERRANOVA, J. P., LE FUR, G. AND SOUBRIÉ, P.: SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience 59: 921-929, 1994.
45. UHL, G. R. AND SNYDEH, S. H.: Regional and subcellular distribution of brain neurotensin. Life Sci. 19: 1827-1832, 1977.
46. UHL, G. R.: Distribution of neurotensin and its receptor in the central nervous system. Ann. N.Y. Acad. Sci. 400: 132-149, 1982.
47. WACHI, M., OKUDA, M., TOGASHI, S., MIYASHITA, O. AND WAKAHOI, T.: Effects of methamphetamine administration on brain neurotensin-like immunoreactivity in rats. Neurosci. Lett. 78: 222-226, 1987.
48. WAGSTAFF, J. D., GIBB, J. W. AND HANSON, G. R.: Dopamine D-2 regulation of neurotensin release from striatum and nucleus accumbens as measured by microdialysis. Abst. Soc. Neurosci. 20: 1146, 1994a.
49. WAGSTAFF, J. D., BUSH, L. G., GIBB, J. W. AND HANSON, G. R.: Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Br. Res. 665: 237-244, 1994b.
50. WAGSTAFF, J. D., GIBB, J. W. AND HANSON, G. R.: Dopamine D-2 receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. Brain Res. 1996, in press.
51. WIDERLOV, E., LINDSTROM, L. H., BESEV, G., MANBERG, P. J., NEMEROFF, C. B., BREESE, G. R., KIZER, J. S. AND PRANGE, A. J.: Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment. Am. J. Psychiatr. 139: 1122-1126, 1982.